Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 69095897

Next Previous
X
Search
Drug Profile

JNJ 69095897

Alternative Names: JNJ-69095897

Latest Information Update: 23 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 10 Jun 2021 Janssen Research & Development plans a phase I pharmacokinetics trial (In volunteers) in Netherlands (PO) (NCT04920578)
  • 01 Jun 2021 Thes term addition and mapping request sent, awaiting CTP, the product is not listed on the company website, created profile based on single source, added licensing availability info based on website
  • 01 Jun 2021 JNJ 69095897 is available for licensing as of 01 Jun 2021. https://www.janssen.com/belgium/collaboration (Janssen Research & Development pipeline, June 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top